Global medical device maker specializing in cardiovascular (structural heart, electrophysiology), endoscopy and urology devices.
Global medical device maker specializing in cardiovascular (structural heart, electrophysiology), endoscopy and urology devices.
Sells single-use devices used in each procedure, through its own sales force and clinical staff who train physicians, so revenue follows procedure volume. Hospitals buy under negotiated purchasing contracts. Growth has come partly from bought technology, such as the Farapulse ablation system acquired in 2021, rather than only internal development.
Moat: wide (IP / patents, switching costs, installed base). Leading positions in structural heart (Watchman) and electrophysiology with strong physician training lock-in.
Headquarters: Marlborough, Massachusetts, USA · Founded: 1979 · Employees: 59,000
Size Boston Scientific (BSX) is a United States Health Care company (Medical Specialties) with a market value of $63.3B, the 209th largest of 3,085 United States companies the cockpit tracks. Shares closed at $43.64 on 18 Nov 2026.
Performance Over six months the shares fell 23.0%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +8.8%); the operating margin is 21.4% (peer median 23.5%).
Valuation It trades at 14.1× forward earnings against a peer median of 27.2× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points above its cost of capital (7.7% WACC).
Credit Boston Scientific has 7 bonds outstanding ($4.26B), rated A- by the agencies and trading like A at a weighted spread of 75 bp.
Short interest Short interest is 2.4% of the free float (30 Oct 2026).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $21.1B | $20.1B | $16.7B | $14.2B | $12.7B |
| Revenue growth | — | +20% | +18% | +12% | — |
| Gross profit | $13.8B | $13.1B | $10.3B | $8.83B | $7.71B |
| EBITDA | $5.95B | $5.44B | $3.90B | $3.38B | $2.96B |
| Net income | $3.50B | $2.90B | $1.85B | $1.59B | $698M |
| Free cash flow | $3.33B | $3.66B | $2.65B | $1.79B | $938M |
| Capital expenditure | $903M | $876M | $790M | $711M | $588M |
| Total debt | $12.0B | $12.0B | $11.2B | $9.49B | $9.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Edwards Lifesciences EW | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BSX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | +6.1% | 3rd lowest of 21 |
| 6-month return | -23.0% | +26.4% | lowest of 21 |
| Distance from 52-week high | -57.2% | -9.1% | lowest of 21 |
| Revenue growth (TTM) | +8.9% | +8.8% | 11th highest of 21 |
| Operating margin | 21.4% | 23.5% | 10th lowest of 21 |
| Forward P/E | 14.1× | 27.2× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 5.8% | 16.5% | 5th least demanding of 21 |
| Growth delivered (Del g) | +15.2% | +7.1% | 3rd highest of 21 |
| Hurdle (Req g minus delivered) | -9.4 pp | +5.6 pp | least demanding of 21 |
| ROIC minus cost of capital | +1.9 pp | +5.9 pp | 7th lowest of 21 |
| EV / EBITDA | 12.6× | 20.2× | 3rd cheapest of 20 |
| Net debt / EBITDA | 1.9× | 1.5× | 7th most indebted of 20 |
| Bond spread | 75 bp | 75 bp | 5th widest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Intuitive Surgical ISRG | United States | $146B | -6% | +20% | 32% | 34.8× | 29.6% | +18.2% |
Boston Scientific has 7 bonds outstanding with $4.26B face value. The agencies rate it A-; its bonds trade like A. Weighted yield 5.14%, a spread of 75 bp over government bonds.